According to the Complaint, Momo operates a mobile-based social and entertainment platform in the PRC.
Recent Security Class Actions
According to the Complaint, Intersect is a commercial drug delivery company that purports to develop products for patients with ear, nose, and throat conditions. The Company's PROPEL family of products are used in conjunction with sinus surgery, and the Company's SINUVA sinus implant is used to treat patients who have had surgery yet suffer from recurrent sinus obstruction due to polyps.
According to the Complaint, Jumia characterizes itself as the leading pan-African e-commerce platform, which it represents to consist of: (i) a marketplace that connects sellers with consumers; (ii) a package shipment and delivery service; and (iii) a payment service.
According to the Complaint, Nabriva Therapeutics plc is a biopharmaceutical company that purports to develop novel antiinfective agents to treat serious infections. One of the Company's product candidates is CONTEPO, an epoxide antibiotic developed by Zavante Therapeutics ("Zavante"), which the Company acquired in July 2018.
According to the Complaint, Indivior together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The Company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia.
According to the Complaint, APYX Medical Corporation is a medical technology company that purportedly develops J-Plasma, a plasma-based surgical product for cutting, coagulation and ablation of soft tissue. The Company markets and sells J-Plasma under the brand name Renuvion Cosmetic Technology. The Company claims that it has developed J-Plasma/Renuvion for use in dermal resurfacing procedures. Apyx was formerly known as Bovie Medical Corporation, and its stock traded on the New York Stock Exchange ("NYSE") under the symbol "BVX" until January 1, 2019.
According to the Complaint, Teligent researches, develops, produces, supplies, and sells generic pharmaceutical products.
According to the Complaint, Taronis purportedly operates as an energy company that offers technology solutions to create, process, and produce hydrogen-based fuel through the gasification of carb-rich liquids. Taronis formerly operated under the name of MagneGas Applied Technology Solutions, Inc.
Plaintiff's law firm issued a press release on March 29, 2019 announcing the filing of the lawsuit. The Complaint alleges that during the Class Period, Defendants were engaged in an undisclosed pump and dump scheme that manipulated and artificially inflated the price of First Choice common stock, and failed to disclose their involvement, rendering certain of their public statements materially misleading.
According to the Complaint, American Renal purports to operate as a dialysis services provider in the United States.
